Skip to main content

Table 3 Characteristics of patients who developed dizziness or somnolence

From: Opioid analgesics increase incidence of somnolence and dizziness as adverse effects of pregabalin: a retrospective study

Duration of pregabalin therapy N Developed somnolence or dizziness
 ≤2 weeks 21 (10.8 %) 8 (38.1 %)
 >2 weeks–≤1 month 30 (15.4 %) 7 (23.3 %)
 >1 month–≤2 months 36 (18.5 %) 11 (30.6 %)
 >2 months 108 (55.4 %) 37 (34.3 %)
 Median (day, range) 78 (1–740)  
Dosage N Developed somnolence or dizziness
 Within the defined initial dosage range 166 (85.1 %) 52 (31.3 %)
 Over the defined initial dosage range 29 (14.9 %) 11 (37.9 %)
Concomitant drugs with pregabalin N Developed somnolence or dizziness
 Oral hypoglycemic drugs 28 (14.4 %) 6 (21.4 %)
 Antihypertensive drugs 55 (28.2 %) 15 (27.2 %)
 NSAID 64 (32.8 %) 15 (23.4 %)
 Opioid pain relievers 54 (27.7 %) 25 (46.3 %)
 CNS- depressants 31 (15.9 %) 9 (29.0 %)